Xtant Medical launched Trivium, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling and biological activity.
Trivium features intertwined structures and interconnected porosity that support the attachment and proliferation of a variety of cell types, and is designed to promote robust tissue ingrowth. With superior moldability and handling characteristics, Trivium allows surgeons to place the graft with precision across a wide range of surgical applications.
Trivium is processed using Xtant’s proprietary BacteRinse method, which has been clinically proven over two decades to preserve native bone morphogenetic proteins (BMPs). This ensures Trivium delivers a complete suite of bioavailable growth factors critical to initiating and supporting bone repair.
“Trivium represents a significant advancement in bone grafting technology,” said Sean Browne, President and CEO of Xtant Medical. “By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients.”
Xtant Medical launched Trivium, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling and biological...
Xtant Medical launched Trivium, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling and biological activity.
Trivium features intertwined structures and interconnected porosity that support the attachment and proliferation of a variety of cell types, and is designed to promote robust tissue ingrowth. With superior moldability and handling characteristics, Trivium allows surgeons to place the graft with precision across a wide range of surgical applications.
Trivium is processed using Xtant’s proprietary BacteRinse method, which has been clinically proven over two decades to preserve native bone morphogenetic proteins (BMPs). This ensures Trivium delivers a complete suite of bioavailable growth factors critical to initiating and supporting bone repair.
“Trivium represents a significant advancement in bone grafting technology,” said Sean Browne, President and CEO of Xtant Medical. “By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients.”
Copy to clipboard 
